lonafarnib has been researched along with s-trans,trans-farnesylthiosalicylic acid in 2 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (s-trans,trans-farnesylthiosalicylic acid) | Trials (s-trans,trans-farnesylthiosalicylic acid) | Recent Studies (post-2010) (s-trans,trans-farnesylthiosalicylic acid) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 174 | 5 | 86 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniecki, C; Priefer, R | 1 |
| Eisen, TG; Smalley, KS | 1 |
1 review(s) available for lonafarnib and s-trans,trans-farnesylthiosalicylic acid
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |
1 other study(ies) available for lonafarnib and s-trans,trans-farnesylthiosalicylic acid
| Article | Year |
|---|---|
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Topics: 3T3 Cells; Actins; Alkyl and Aryl Transferases; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cisplatin; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Melanoma; Mice; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Retinoblastoma Protein; Salicylates; Skin Neoplasms; Tumor Cells, Cultured | 2003 |